

Vikram Mathews

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2115758/publications.pdf>

Version: 2024-02-01

282
papers

4,284
citations

136950

32
h-index

144013

57
g-index

286
all docs

286
docs citations

286
times ranked

5100
citing authors

#	ARTICLE	IF	CITATIONS
1	Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet. <i>Blood</i> , 2019, 133, 1630-1643.	1.4	393
2	Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: durable remissions with minimal toxicity. <i>Blood</i> , 2006, 107, 2627-2632.	1.4	313
3	Single-Agent Arsenic Trioxide in the Treatment of Newly Diagnosed Acute Promyelocytic Leukemia: Long-Term Follow-Up Data. <i>Journal of Clinical Oncology</i> , 2010, 28, 3866-3871.	1.6	235
4	Recruitment of Bone Marrow-Derived Endothelial Cells to Sites of Pancreatic β -Cell Injury. <i>Diabetes</i> , 2004, 53, 91-98.	0.6	172
5	Glutathione S-transferase M1 polymorphism: a risk factor for hepatic venoocclusive disease in bone marrow transplantation. <i>Blood</i> , 2004, 104, 1574-1577.	1.4	155
6	Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24-month follow-up. <i>American Journal of Hematology</i> , 2014, 89, 732-742.	4.1	102
7	Acute myeloid leukaemia: challenges and real world data from India. <i>British Journal of Haematology</i> , 2015, 170, 110-117.	2.5	96
8	Comparison of Clinical Outcomes of Patients with Relapsed Acute Promyelocytic Leukemia Induced with Arsenic Trioxide and Consolidated with Either an Autologous Stem Cell Transplant or an Arsenic Trioxide-Based Regimen. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 1479-1484.	2.0	84
9	Stem cell expression of the AML1/ETO fusion protein induces a myeloproliferative disorder in mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 15184-15189.	7.1	81
10	Improved Clinical Outcomes of High Risk β^2 Thalassemia Major Patients Undergoing a HLA Matched Related Allogeneic Stem Cell Transplant with a Treosulfan Based Conditioning Regimen and Peripheral Blood Stem Cell Grafts. <i>PLoS ONE</i> , 2013, 8, e61637.	2.5	78
11	A New Stratification Strategy That Identifies a Subset of Class III Patients with an Adverse Prognosis among Children with β^2 Thalassemia Major Undergoing a Matched Related Allogeneic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 889-894.	2.0	67
12	Arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: A single center experience. <i>American Journal of Hematology</i> , 2002, 70, 292-299.	4.1	63
13	Role of NF-E2 related factor 2 (Nrf2) on chemotherapy resistance in acute myeloid leukemia (AML) and the effect of pharmacological inhibition of Nrf2. <i>PLoS ONE</i> , 2017, 12, e0177227.	2.5	61
14	Dapsone for chronic idiopathic thrombocytopenic purpura in children and adults – a report on 90 patients. <i>European Journal of Haematology</i> , 2005, 75, 328-331.	2.2	57
15	Long-term outcome following splenectomy for chronic and persistent immune thrombocytopenia (ITP) in adults and children. <i>Annals of Hematology</i> , 2016, 95, 1429-1434.	1.8	56
16	Impact of FLT3 mutations and secondary cytogenetic changes on the outcome of patients with newly diagnosed acute promyelocytic leukemia treated with a single agent arsenic trioxide regimen. <i>Haematologica</i> , 2007, 92, 994-995.	3.5	54
17	Increased ABCG2 Expression Could Be Responsible for Resistance to Imatinib Mesylate in Patients with Chronic Myeloid Leukemia Who Do Not Have Mutations in BCR-ABL Kinase Domain. <i>Blood</i> , 2008, 112, 5026-5026.	1.4	53
18	Treatment of children with acute lymphoblastic leukemia in India using a BFM protocol. <i>Pediatric Blood and Cancer</i> , 2008, 51, 621-625.	1.5	48

#	ARTICLE	IF	CITATIONS
19	Related and unrelated donor transplantation for β^2 -thalassemia major: results of an international survey. <i>Blood Advances</i> , 2019, 3, 2562-2570.	5.2	48
20	Enhanced green fluorescent protein targeted to the Sca-1 (Ly-6A) locus in transgenic mice results in efficient marking of hematopoietic stem cells in vivo. <i>Experimental Hematology</i> , 2003, 31, 159-167.	0.4	47
21	Role of minimal residual disease monitoring in acute promyelocytic leukemia treated with arsenic trioxide in frontline therapy. <i>Blood</i> , 2012, 119, 3413-3419.	1.4	45
22	Identification of Candidate Alkylator-Induced Cancer Susceptibility Genes by Whole Genome Scanning in Mice. <i>Cancer Research</i> , 2006, 66, 5029-5038.	0.9	44
23	Cytidine deaminase genetic variants influence RNA expression and cytarabine cytotoxicity in acute myeloid leukemia. <i>Pharmacogenomics</i> , 2012, 13, 269-282.	1.3	43
24	Comparison of Newly Diagnosed and Relapsed Patients with Acute Promyelocytic Leukemia Treated with Arsenic Trioxide: Insight into Mechanisms of Resistance. <i>PLoS ONE</i> , 2015, 10, e0121912.	2.5	43
25	RNA expression of genes involved in cytarabine metabolism and transport predicts cytarabine response in acute myeloid leukemia. <i>Pharmacogenomics</i> , 2015, 16, 877-890.	1.3	41
26	TARGET: a survey of real-world management of chronic myeloid leukaemia across 33 countries. <i>British Journal of Haematology</i> , 2020, 190, 869-876.	2.5	40
27	TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA WITH SINGLE-AGENT ARSENIC TRIOXIDE. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2011, 3, e2011056.	1.3	39
28	MERGE: A Multinational, Multicenter Observational Registry for Myeloproliferative Neoplasms in Asia, including Middle East, Turkey, and Algeria. <i>Cancer Medicine</i> , 2020, 9, 4512-4526.	2.8	39
29	Choice of conditioning regimens for bone marrow transplantation in severe aplastic anemia. <i>Blood Advances</i> , 2019, 3, 3123-3131.	5.2	37
30	Standardizing minimal residual disease by flow cytometry for precursor B lineage acute lymphoblastic leukemia in a developing country. <i>Cytometry Part B - Clinical Cytometry</i> , 2012, 82B, 252-258.	1.5	36
31	Plasmacytoid Dendritic Cell Count on Day 28 in HLA-Matched Related Allogeneic Peripheral Blood Stem Cell Transplant Predicts the Incidence of Acute and Chronic GVHD. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 344-350.	2.0	35
32	Infections in children undergoing allogeneic bone marrow transplantation in India. <i>Pediatric Transplantation</i> , 2006, 10, 48-54.	1.0	34
33	Effect of Postremission Therapy before Reduced-Intensity Conditioning Allogeneic Transplantation for Acute Myeloid Leukemia in First Complete Remission. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 202-208.	2.0	33
34	Fludarabine based reduced intensity conditioning regimens in children undergoing allogeneic stem cell transplantation for severe aplastic anemia. <i>Pediatric Transplantation</i> , 2008, 12, 14-19.	1.0	32
35	Mechanisms and management of coagulopathy in acute promyelocytic leukemia. <i>Thrombosis Research</i> , 2018, 164, S82-S88.	1.7	32
36	Stromal cells downregulate miR-23a-5p to activate protective autophagy in acute myeloid leukemia. <i>Cell Death and Disease</i> , 2019, 10, 736.	6.3	31

#	ARTICLE	IF	CITATIONS
37	Three siblings with Woodhouseâ€™Sakati syndrome in an Indian family. <i>Clinical Dysmorphology</i> , 2008, 17, 57-60.	0.3	30
38	Classification of myeloid neoplasms/acute leukemia: Global perspectives and the international consensus classification approach. <i>American Journal of Hematology</i> , 2022, 97, 514-518.	4.1	30
39	Carbonyl reductase 1 expression influences daunorubicin metabolism in acute myeloid leukemia. <i>European Journal of Clinical Pharmacology</i> , 2012, 68, 1577-1586.	1.9	29
40	The t(6;9)(p22;q34) in myeloid neoplasms: a retrospective study of 16 cases. <i>Cancer Genetics and Cytogenetics</i> , 2010, 203, 297-302.	1.0	27
41	Clinical Profile and Outcomes of Patients with Î² Thalassemia Major and Hepatitis C Virus Infection Undergoing an Allogeneic Stem Cell Transplant. <i>Blood</i> , 2012, 120, 4160-4160.	1.4	27
42	ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IS SUPERIOR TO IMMUNOSUPPRESSIVE THERAPY IN INDIAN CHILDREN WITH APLASTIC ANEMIAâ€™A SINGLE-CENTER ANALYSIS OF 100 PATIENTS. <i>Pediatric Hematology and Oncology</i> , 2010, 27, 122-131.	0.8	26
43	Invasive fungal infection following chemotherapy for acute myeloid leukaemiaâ€™Experience from a developing country. <i>Mycoses</i> , 2017, 60, 686-691.	4.0	26
44	In utero origin of myelofibrosis presenting in adult monozygotic twins. <i>Nature Medicine</i> , 2022, 28, 1207-1211.	30.7	26
45	Surgery for Hemophilia in Developing Countries. <i>Seminars in Thrombosis and Hemostasis</i> , 2005, 31, 538-543.	2.7	25
46	Frequency of TPMT alleles in Indian patients with acute lymphatic leukemia and effect on the dose of 6-mercaptopurine. <i>Medical Oncology</i> , 2010, 27, 1046-1049.	2.5	25
47	ATP-binding cassette transporter expression in acute myeloid leukemia: association with<i>in vitro</i>cytotoxicity and prognostic markers. <i>Pharmacogenomics</i> , 2017, 18, 235-244.	1.3	24
48	Spectrum of<i>BCR-ABL</i>kinase domain mutations in patients with chronic myeloid leukemia from India with suspected resistance to imatinib-mutations are rare and have different distributions. <i>Leukemia and Lymphoma</i> , 2009, 50, 2092-2095.	1.3	22
49	Allogeneic Stem Cell Transplantation for Thalassemia Major. <i>Hematology/Oncology Clinics of North America</i> , 2014, 28, 1187-1200.	2.2	22
50	Pharmacokinetics and Pharmacodynamics of Treosulfan in Patients With Thalassemia Major Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 104, 575-583.	4.7	22
51	Post-Transplant Cyclophosphamide as Sole Graft-versus-Host Disease Prophylaxis Is Feasible in Patients Undergoing Peripheral Blood Stem Cell Transplantation for Severe Aplastic Anemia Using Matched Sibling Donors. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 494-500.	2.0	22
52	Allogeneic Hematopoietic Cell Transplantation in Patients Aged 50Years or Older with Severe Aplastic Anemia. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 488-495.	2.0	21
53	Arsenic Trioxide (As2O3) in the Treatment of Patients with Newly Diagnosed Acute Promyelocytic Leukemia (APML) - Toxicity and Outcome.. <i>Blood</i> , 2004, 104, 889-889.	1.4	21
54	Polymyositis - an unusual manifestation of chronic graft-versus-host disease. <i>Rheumatology International</i> , 2001, 20, 169-170.	3.0	20

#	ARTICLE	IF	CITATIONS
55	Management of Hemophilia in Patients with Inhibitors: The Perspective from Developing Countries. Seminars in Thrombosis and Hemostasis, 2009, 35, 820-826.	2.7	20
56	Dendritic Cell Count in the Graft Predicts Relapse in Patients with Hematologic Malignancies Undergoing an HLA-Matched Related Allogeneic Peripheral Blood Stem Cell Transplant. Biology of Blood and Marrow Transplantation, 2010, 16, 854-860.	2.0	20
57	Population pharmacokinetics of Daunorubicin in adult patients with acute myeloid leukemia. Cancer Chemotherapy and Pharmacology, 2016, 78, 1051-1058.	2.3	20
58	Cellular Immune Reconstitution and Its Impact on Clinical Outcome in Children with β^2 Thalassemia Major Undergoing a Matched Related Myeloablative Allogeneic Bone Marrow Transplant. Biology of Blood and Marrow Transplantation, 2009, 15, 597-609.	2.0	19
59	Cytogenetic analysis of acute myeloid leukemia with t(8;21) from a tertiary care center in India with correlation between clinicopathologic characteristics and molecular analysis. Leukemia and Lymphoma, 2012, 53, 103-109.	1.3	19
60	The use of a fludarabine-based conditioning regimen in patients with severe aplastic anemia – a retrospective analysis from three Indian centers. Clinical Transplantation, 2013, 27, 923-929.	1.6	19
61	Impact of pretransplant splenectomy on patients with β^2 thalassemia major undergoing a matched related allogeneic stem cell transplantation. Pediatric Transplantation, 2009, 13, 171-176.	1.0	18
62	Use of Non-Cryopreserved Peripheral Blood Stem Cells Is Associated with Adequate Engraftment in Patients with Multiple Myeloma Undergoing an Autologous Transplant. Biology of Blood and Marrow Transplantation, 2018, 24, e31-e35.	2.0	18
63	Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report. Blood Advances, 2020, 4, 3180-3190.	5.2	18
64	Risk factors of thrombosis in abdominal veins. World Journal of Gastroenterology, 2008, 14, 4518.	3.3	18
65	Primary Immunodeficiencies in India: Molecular Diagnosis and the Role of Next-Generation Sequencing. Journal of Clinical Immunology, 2021, 41, 393-413.	3.8	17
66	Efficacy of stem cell in improvement of left ventricular function in acute myocardial infarction - MI3 Trial. Indian Journal of Medical Research, 2015, 142, 165.	1.0	17
67	Myeloproliferative neoplasms working group consensus recommendations for diagnosis and management of primary myelofibrosis, polycythemia vera, and essential thrombocythemia. Indian Journal of Medical and Paediatric Oncology, 2015, 36, 3.	0.2	16
68	Clinical manifestations of combined factor V and VIII deficiency: A series of 37 cases from a single center in India. American Journal of Hematology, 2010, 85, 538-539.	4.1	15
69	Allogeneic Stem Cell Transplant for Acute Myeloid Leukemia: Evolution of an Effective Strategy in India. Journal of Global Oncology, 2017, 3, 773-781.	0.5	15
70	Fludarabine-based reduced intensity conditioning regimens for allogeneic hematopoietic stem cell transplantation in patients with aplastic anemia and fungal infections. Clinical Transplantation, 2009, 23, 228-232.	1.6	14
71	Role of imatinib in the treatment of pediatric onset indolent systemic mastocytosis: a case report. Journal of Dermatological Treatment, 2013, 24, 481-483.	2.2	14
72	Leukocyte Adhesion Deficiency-I: Clinical and Molecular Characterization in an Indian Population. Indian Journal of Pediatrics, 2016, 83, 799-804.	0.8	14

#	ARTICLE	IF	CITATIONS
73	Arsenic Trioxide Enhances the NK Cell Cytotoxicity Against Acute Promyelocytic Leukemia While Simultaneously Inhibiting Its Bio-Genesis. <i>Frontiers in Immunology</i> , 2018, 9, 1357.	4.8	14
74	A phase II study evaluating the role of bortezomib in the management of relapsed acute promyelocytic leukemia treated upfront with arsenic trioxide. <i>Cancer Medicine</i> , 2020, 9, 2603-2610.	2.8	14
75	Microenvironment and drug resistance in acute myeloid leukemia: Do we know enough?. <i>International Journal of Cancer</i> , 2022, 150, 1401-1411.	5.1	14
76	Generic imatinib: the real-deal or just a deal?. <i>Leukemia and Lymphoma</i> , 2014, 55, 2678-2680.	1.3	13
77	Management of relapse in acute promyelocytic leukaemia treated with upâ€front arsenic trioxideâ€based regimens. <i>British Journal of Haematology</i> , 2021, 192, 292-299.	2.5	13
78	Induction Related Mortality in Acute Myeloid Leukemia: Multivariate Model of Predictive Score from the Indian Acute Leukemia Research Database (INwARD) of the Hematology Cancer Consortium (HCC). <i>Blood</i> , 2019, 134, 2615-2615.	1.4	13
79	A novel Î-globin gene mutation (HBD: c.323G>A) masking the diagnosis of Î-thalassemia: a first report from India. <i>International Journal of Hematology</i> , 2012, 95, 570-572.	1.6	12
80	Association of growth differentiation factor 15 (GDF15) polymorphisms with serum GDF15 and ferritin levels in Î-thalassemia. <i>Annals of Hematology</i> , 2014, 93, 2093-2095.	1.8	12
81	Leukocyte derived chemotaxin 2 (ALECT2) amyloidosis. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2015, 7, e2015043.	1.3	12
82	Adult Acute Lymphoblastic Leukemia: Limitations of Intensification of Therapy in a Developing Country. <i>Journal of Global Oncology</i> , 2018, 4, 1-12.	0.5	12
83	NK Cell Mediated Cytotoxicity Against Malignant Promyelocytes Enhanced By Arsenic Trioxide: Potential Clinical Relevance. <i>Blood</i> , 2013, 122, 1455-1455.	1.4	12
84	Clinicopathological features of hepatosplenic T cell lymphoma: a single centre experience from India. <i>Leukemia and Lymphoma</i> , 2012, 53, 609-615.	1.3	11
85	Drugâ€resistant organisms are common in fecal surveillance cultures, predict bacteremia and correlate with poorer outcomes in patients undergoing allogeneic stem cell transplants. <i>Transplant Infectious Disease</i> , 2020, 22, e13273.	1.7	11
86	Risk Stratification without a Liver Biopsy of Patients with Î-thalassemia Major Undergoing a Matched Related Allogeneic Bone Marrow Transplant.. <i>Blood</i> , 2009, 114, 659-659.	1.4	11
87	Clinical Outcomes in Multiple Myeloma Post-Autologous Transplantationâ€A Single Centre Experience. <i>Indian Journal of Hematology and Blood Transfusion</i> , 2019, 35, 215-222.	0.6	10
88	Effect of Conditioning Regimen Dose Reduction in Obese Patients Undergoing Autologous Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 480-487.	2.0	10
89	Prognostic plasma biomarkers of early complications and graftâ€versusâ€host disease in patients undergoing allogeneic hematopoietic stem cell transplantation. <i>EJHaem</i> , 2020, 1, 219-229.	1.0	10
90	Combination Lenalidomide/Bortezomib Treatment Synergistically Induces Calpain-Dependent Ikaros Cleavage and Apoptosis in Myeloma Cells. <i>Molecular Cancer Research</i> , 2020, 18, 529-536.	3.4	10

#	ARTICLE	IF	CITATIONS
91	JAK2 exon 12 mutations in cases with JAK2V617F-negative polycythemia vera and primary myelofibrosis. <i>Annals of Hematology</i> , 2020, 99, 983-989.	1.8	10
92	Effect of cytosine arabinoside metabolizing enzyme expression on drug toxicity in acute myeloid leukemia. <i>Annals of Hematology</i> , 2015, 94, 883-885.	1.8	9
93	Second Hematopoietic Stem Cell Transplant for Thalassemia Major: Improved Clinical Outcomes with a Treosulfan-Based Conditioning Regimen. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 103-108.	2.0	9
94	Prevalence of FVIII inhibitors in severe haemophilia A patients: Effect of treatment and genetic factors in an Indian population. <i>Haemophilia</i> , 2019, 25, 67-74.	2.1	9
95	Plasma imatinib levels and ABCB1 polymorphism influences early molecular response and failure-free survival in newly diagnosed chronic phase CML patients. <i>Scientific Reports</i> , 2020, 10, 20640.	3.3	9
96	Outcomes in adolescent and young adult acute lymphoblastic leukaemia: a report from the Indian Acute Leukaemia Research Database (INWARD) of the Hematology Cancer Consortium (HCC). <i>British Journal of Haematology</i> , 2021, 193, e1-e4.	2.5	9
97	International Reporting Scale of <i>BCR-ABL1</i> Fusion Transcript in Chronic Myeloid Leukemia: First Report from India. <i>Acta Haematologica</i> , 2012, 127, 135-142.	1.4	8
98	Outcome of treatment with a low cost protocol in adults with T cell acute lymphoblastic leukemia in a tertiary care center in India. <i>Leukemia and Lymphoma</i> , 2014, 55, 947-949.	1.3	8
99	The t(8;14)(q24.1;q32) and its variant translocations: A study of 34 cases. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2017, 10, 126-134.	0.9	8
100	Spectrum of <i>ELANE</i> mutations in congenital neutropenia: a single-centre study in patients of Indian origin. <i>Journal of Clinical Pathology</i> , 2018, 71, 1046-1050.	2.0	8
101	Dendritic Cell Type 2 Counts on Day 28 in HLA-Matched Related Allogeneic PBSCT Predicts the Incidence of Acute and Chronic GVHD.. <i>Blood</i> , 2006, 108, 2893-2893.	1.4	8
102	Clinical, Cellular and Molecular Differences Between Newly Diagnosed and Relapsed Patients with Acute Promyelocytic Leukemia: Insights Into Mechanisms of Resistance. <i>Blood</i> , 2012, 120, 1390-1390.	1.4	8
103	Real world data with concurrent retinoic acid and arsenic trioxide for the treatment of acute promyelocytic leukemia. <i>Blood Cancer Journal</i> , 2022, 12, 22.	6.2	8
104	Coexistence of aberrant hematopoietic and stromal elements in myelodysplastic syndromes. <i>Blood Cells, Molecules, and Diseases</i> , 2017, 66, 37-46.	1.4	7
105	Allogeneic stem cell transplantation for thalassemia major in India. <i>Pediatric Hematology Oncology Journal</i> , 2017, 2, 114-120.	0.1	7
106	<p>A personalized approach to acute myeloid leukemia therapy: current options</p>. <i>Pharmacogenomics and Personalized Medicine</i> , 2019, Volume 12, 167-179.	0.7	7
107	Comparison of the Efficacy of Innovator Rituximab and its Biosimilars in Diffuse Large B Cell Lymphoma Patients: A Retrospective Analysis. <i>Indian Journal of Hematology and Blood Transfusion</i> , 2020, 36, 71-77.	0.6	7
108	How I treat advanced Hodgkin lymphoma – a global view. <i>British Journal of Haematology</i> , 2020, 190, 837-850.	2.5	7

#	ARTICLE	IF	CITATIONS
109	Evolving Chemotherapy Free Regimens for Acute Promyelocytic Leukemia. <i>Frontiers in Oncology</i> , 2021, 11, 621566.	2.8	7
110	An Antithymocyte Globulin-Free Conditioning Regimen Using Fludarabine and Cyclophosphamide Is Associated with Good Outcomes in Patients Undergoing Matched Related Family Donor Transplantation for Aplastic Anemia. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 409.e1-409.e6.	1.2	7
111	Acute Myeloid Leukemia: Challenges and Real World Data from India. <i>Blood</i> , 2014, 124, 3685-3685.	1.4	7
112	Fluorescence in situ hybridization patterns of BCR/ABL1 fusion in chronic myelogenous leukemia at diagnosis. <i>Indian Journal of Pathology and Microbiology</i> , 2012, 55, 347.	0.2	7
113	Comparison of Clinical Outcomes of Relapsed APL Patients Induced with ATO and Consolidated with Either an Autologous SCT or ATO Based Treatment Regimen.. <i>Blood</i> , 2007, 110, 2880-2880.	1.4	7
114	Polymorphisms in the Immunoregulatory Genes are Associated with Hematopoietic Recovery and Increased Susceptibility to Bacterial Infections in Patients with Thalassaemia Major Undergoing Matched Related Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 1219-1226.	2.0	6
115	ABC6 RNA expression in leukemiasâ€™ expression is low in acute promyelocytic leukemia and FLT3-ITD-positive acute myeloid leukemia. <i>Annals of Hematology</i> , 2014, 93, 509-512.	1.8	6
116	Allele Specific PCR: A Cost Effective Screening Method for MPL Mutations in Myeloproliferative Neoplasms. <i>Indian Journal of Hematology and Blood Transfusion</i> , 2018, 34, 765-767.	0.6	6
117	A Low Incidence of Cytomegalo Virus Infection Following Allogeneic Hematopoietic Stem Cell Transplantation Despite a High Seroprevalence. <i>Indian Journal of Hematology and Blood Transfusion</i> , 2018, 34, 636-642.	0.6	6
118	Towards access for all: 1st Working Group Report for the Global Gene Therapy Initiative (GGTI). <i>Gene Therapy</i> , 2023, 30, 216-221.	4.5	6
119	Outcomes in Adolescent and Young Adult (AYA) Acute Lymphoblastic Leukemia (ALL): A Report from the Indian Acute Leukemia Research Database (INwARD) of the Hematology Cancer Consortium (HCC). <i>Blood</i> , 2019, 134, 1306-1306.	1.4	6
120	Population Pharmacokinetics of Fludarabine and Treosulfan in Patients with Thalassemia Undergoing Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2015, 126, 3120-3120.	1.4	6
121	Haploidentical transplantation is feasible and associated with reasonable outcomes despite major infective complicationsâ€™A single center experience from India. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 45.e1-45.e8.	1.2	6
122	Six Novel Mutations Including Triple Heterozygosity for Phe31Ser, 514delT and 516Tâ†’G Mutations in Factor X Gene Is Responsible for Congenital Factor X Deficiency in Patients of Indian and Nepali Origin.. <i>Blood</i> , 2004, 104, 1042-1042.	1.4	6
123	BK polyomavirus hemorrhagic cystitis in hematopoietic cell transplant recipients. <i>Journal of Global Infectious Diseases</i> , 2022, 14, 17.	0.5	6
124	Role of endovascular embolization in treatment of acute bleeding complications in haemophilia patients. <i>British Journal of Radiology</i> , 2016, 89, 20151064.	2.2	5
125	Atypical<i>BCR-ABL1</i>fusion transcripts in adult B-acute lymphoblastic leukemia, including a novel fusion transcript-e8a1. <i>Leukemia and Lymphoma</i> , 2016, 57, 2481-2484.	1.3	5
126	Heterogeneity of Mesenchymal Stromal Cells in Myelodysplastic Syndrome-with Multilineage Dysplasia (MDS-MLD). <i>Indian Journal of Hematology and Blood Transfusion</i> , 2019, 35, 223-232.	0.6	5

#	ARTICLE	IF	CITATIONS
127	Systematic application of fluorescence in situ hybridization and immunophenotype profile for the identification of ZNF384 gene rearrangements in B cell acute lymphoblastic leukemia. International Journal of Laboratory Hematology, 2021, 43, 658-663.	1.3	5
128	Pharmacokinetic and Pharmacodynamic Evaluation of a Biosimilar Rituximab in Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) Treated with R-CHOP (Rituximab, Cyclophosphamide, Adriamycin,) Tj ETQq04 0 rgBT5/Overlock	0.4	5
129	Metabolic Rewiring Drives Resistance to Arsenic Trioxide in Acute Promyelocytic Leukemia. Blood, 2016, 128, 3956-3956.	1.4	5
130	Peripheral T cell lymphoma: Clinico-pathological characteristics & outcome from a tertiary care centre in south India. Indian Journal of Medical Research, 2018, 147, 464.	1.0	5
131	Molecular basis of hereditary factor V deficiency in India: Identification of four novel mutations and their genotype-phenotype correlation. Thrombosis and Haemostasis, 2011, 105, 1120-1123.	3.4	4
132	Generic Imatinib: The real-deal or just a deal?. Leukemia and Lymphoma, 2014, , 1-8.	1.3	4
133	Clinical, Hematological and Molecular Analysis of Homozygous Hb E (<i>HBB</i>: c.79Gâ€‰%>â€‰%A) in the Indian Population. Hemoglobin, 2016, 40, 16-19.	0.8	4
134	Outcomes Following Allogeneic Stem Cell Transplantation Using Non-sibling Family Donors. Indian Journal of Hematology and Blood Transfusion, 2019, 35, 43-49.	0.6	4
135	A Prospective Observational Multi-institutional Study on Invasive Fungal Infections Following Chemotherapy for Acute Myeloid Leukemia (MISFIC Study): A Real World Scenario from India. Indian Journal of Hematology and Blood Transfusion, 2020, 36, 97-103.	0.6	4
136	Resource utilization and cost effectiveness of treating acute promyelocytic leukaemia using generic arsenic trioxide. British Journal of Haematology, 2020, 189, 269-278.	2.5	4
137	Prognostic value of MRD monitoring based on<i>BCR-ABL1</i>copy numbers in Philadelphia chromosome positive acute lymphoblastic leukemia. Leukemia and Lymphoma, 2020, 61, 3468-3475.	1.3	4
138	Higher Incidence of Graft Rejection in Non-Sibling Fully Matched Related Donor Stem Cell Transplants for Thalassemia Major: A Cautionary Note. Blood, 2018, 132, 2178-2178.	1.4	4
139	Hematological Cancer Consortium: Multi-Center Acute Myeloid Leukemia Registry Data from India. Blood, 2018, 132, 4006-4006.	1.4	4
140	Arsenic Trioxide Resistance: More to It Than Mutations in PML-RARÎ±. Blood, 2014, 124, 3605-3605.	1.4	4
141	DNA-mediated adjuvant immunotherapy extends survival in two different mouse models of myeloid malignancies. Oncotarget, 2015, 6, 32494-32508.	1.8	4
142	Metabolic adaptation drives arsenic trioxide resistance in acute promyelocytic leukemia. Blood Advances, 2022, 6, 652-663.	5.2	4
143	Impact of Myeloproliferative Neoplasms (MPNs) on Health-Related Quality of Life (HRQOL) and Medical Resource Utilization: Results from the MERGE Registry. Blood, 2018, 132, 4311-4311.	1.4	4
144	Single Dose of Ivermectin is not Useful in Patients with Hematological Disorders and COVID-19 Illness: A Phase II B Open Labelled Randomized Controlled Trial. Indian Journal of Hematology and Blood Transfusion, 2022, 38, 615-622.	0.6	4

#	ARTICLE	IF	CITATIONS
145	Treatment rates of paediatric acute myeloid leukaemia: a view from three tertiary centres in India – response to Gupta <i>et al</i> . British Journal of Haematology, 2016, 175, 347-349.	2.5	3
146	Molecular characterization of novel Adeno-associated virus variants infecting human tissues. Virus Research, 2019, 272, 197716.	2.2	3
147	Evaluation of nonneutralizing antibodies against factor VIII in severe haemophilia A patients from India. Blood Coagulation and Fibrinolysis, 2019, 30, 337-340.	1.0	3
148	Outcome of iron reduction therapy in ex-thalasseemics. PLoS ONE, 2021, 16, e0238793.	2.5	3
149	Very Long Term Follow-up Data of Pediatric Acute Promyelocytic Leukemia Treated with Upfront Arsenic-Trioxide Based Regimens. Blood, 2018, 132, 1400-1400.	1.4	3
150	Clinical and Molecular Characterization of Fanconi Anemia: An Indian Perspective. Blood, 2014, 124, 2938-2938.	1.4	3
151	Mesenchymal stromal stem cell therapy in advanced interstitial lung disease - Anaphylaxis and short-term follow-up. Lung India, 2015, 32, 486.	0.7	3
152	Polymorphisms in Coagulant and Inflammatory Genes Modify the Phenotype of Severe Hemophilia A and B.. Blood, 2006, 108, 1009-1009.	1.4	3
153	Polymorphism in the IFN- β Gene Is Associated with Severe Acute Graft Versus Host Disease in β^2 Thalassemia Major Patients Undergoing Matched Related Hematopoietic Stem Cell Transplantation (HSCT).. Blood, 2007, 110, 1105-1105.	1.4	3
154	Management of Relapse in Acute Promyelocytic Leukemia Treated with Upfront Arsenic Trioxide Based Regimens. Blood, 2018, 132, 666-666.	1.4	3
155	Myeloproliferative neoplasms – a global view. British Journal of Haematology, 2022, , .	2.5	3
156	De-escalation of treatment for acute promyelocytic leukaemia?. Lancet Haematology, the, 2015, 2, e348-e349.	4.6	2
157	Pharmacokinetics and Efficacy of Generic Melphalan Is Comparable to Innovator Formulation in Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplantation. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, 130-135.e1.	0.4	2
158	Do Bone Density, Bone Microarchitecture, and Body Composition Differ in Recipients of Allogeneic Hematopoietic Stem Cell Transplant? A Cross-Sectional Study from Southern India. Biology of Blood and Marrow Transplantation, 2020, 26, 540-545.	2.0	2
159	Impact of imaging modality on clinical outcome in Hodgkin lymphoma in a resource constraint setting. British Journal of Haematology, 2020, 188, 930-934.	2.5	2
160	Mutation profile in BCR-ABL1-negative myeloproliferative neoplasms: A single-center experience from India. Hematology/ Oncology and Stem Cell Therapy, 2021, , .	0.9	2
161	Haplo-Identical Transplants Using Post Transplant Cyclophosphamide (PTCy) Are Associated with Good Outcomes If Transplanted with Early Disease - a Single Centre Analysis from India. Blood, 2018, 132, 4652-4652.	1.4	2
162	Outcome of Immune Tolerance Induction Using an Extended Half-Life Clotting Factor Concentrate – Recombinant Factor VIII Fc (Eloctate, C) – a Report from India. Blood, 2018, 132, 2494-2494.	1.4	2

#	ARTICLE	IF	CITATIONS
163	Reduced Intensity Conditioning (RIC) with Fludarabine, Busulfan and Cyclophosphamide for High Risk Patients with Thalassemia Major Undergoing Allogeneic Bone Marrow Transplantation Results in High Rejection Rates.. Blood, 2007, 110, 1998-1998.	1.4	2
164	Population Pharmacokinetics of Cyclophosphamide in Patients with Thalassemia Major Undergoing HSCT Shows Body Weight, CYP450, GST and ALDH Polymorphisms as Covariates Explaining Inter-Individual Variation.. Blood, 2009, 114, 1182-1182.	1.4	2
165	Single Agent Arsenic Trioxide Regimen for the Treatment of Newly Diagnosed Acute Promyelocytic Leukemia: Initial Results of a Multicenter Randomized Controlled Study From India to Study the Optimal Duration of Arsenic Trioxide Maintenance Therapy (IAPLSG04).. Blood, 2009, 114, 2082-2082.	1.4	2
166	Polymorphisms in the CYP450 Genes Influences Regimen Related Toxicity and Outcome in Patients with Beta Thalassemia Major Undergoing HSCT.. Blood, 2009, 114, 869-869.	1.4	2
167	Bosutinib As Therapy for Chronic Phase Chronic Myeloid Leukemia Following Resistance or Intolerance to Imatinib: 36-Month Minimum Follow-up Update. Blood, 2012, 120, 3779-3779.	1.4	2
168	Harnessing Gene Expression Profiling In Search Of New Candidate Genes For Ara-C Resistance In Acute Myeloid Leukemia. Blood, 2013, 122, 1299-1299.	1.4	2
169	A 5'UTR Polymorphism in NT5E Gene Influences Outcome in Patients with Acute Myeloid Leukemia Undergoing Hematopoietic Stem Cell Transplantation with Fludarabine Based Conditioning Regimen. Blood, 2016, 128, 984-984.	1.4	2
170	Impact of donor telomere length on survival in patients undergoing matched sibling donor transplantation for aplastic anaemia. British Journal of Haematology, 2022, 196, 724-734.	2.5	2
171	Myeloid Derived Suppressor Cells in Acute Leukemia and Its Association with Conventional Cytogenetic and Molecular Risk Factors. Blood, 2012, 120, 1446-1446.	1.4	2
172	Allogeneic Stem Cell Transplantation for Thalassemia Major. , 2017, , 343-357.		2
173	Endothelial Activation and Stress Index-Measured Pretransplantation Predicts Transplantation-Related Mortality in Patients with Thalassemia Major Undergoing Transplantation with Thiotepa, Treosulfan, and Fludarabine Conditioning. Transplantation and Cellular Therapy, 2022, 28, 356.e1-356.e6.	1.2	2
174	NovelNPM1mutation in the 3â€™-untranslated region identified in two patients with acute myeloid leukemia. Leukemia and Lymphoma, 2014, 55, 1421-1424.	1.3	1
175	Summary of the Highlights of 2019 ASTCT Meeting by INDUS BMT Group at Chennai, India. Indian Journal of Hematology and Blood Transfusion, 2019, 35, 409-415.	0.6	1
176	Endocrine Challenges and Metabolic Profile in Recipients of Allogeneic Haematopoietic Stem Cell Transplant: A Cross-Sectional Study from Southern India. Indian Journal of Hematology and Blood Transfusion, 2020, 36, 484-490.	0.6	1
177	Screening of genetic variants in ELANE mutation negative congenital neutropenia by next generation sequencing. Journal of Clinical Pathology, 2020, 73, 322-327.	2.0	1
178	Safety of peripheral blood stem cell harvest in children under anaesthesia in the day care setting â€” A single centre experience. Transfusion and Apheresis Science, 2021, 60, 102962.	1.0	1
179	BCR-ABL1 kinase domain mutation analysis by next generation sequencing detected additional mutations in chronic myeloid leukemia patients with suboptimal response to imatinib. Leukemia and Lymphoma, 2021, 62, 1528-1531.	1.3	1
180	Disease Status at Transplant has a Significant Impact on Outcomes of Autologous Transplantation (ASCT) in Patients with Hodgkin Lymphomaâ€”A Single Center Experience. Indian Journal of Hematology and Blood Transfusion, 2022, 38, 290-298.	0.6	1

#	ARTICLE	IF	CITATIONS
181	Related and Unrelated Donor Transplantation for β^2 Thalassemia Major: Results of an International Survey. <i>Blood</i> , 2018, 132, 308-308.	1.4	1
182	Myeloproliferative Neoplasms in Asia, Including Middle East, Turkey, and Algeria: Epidemiological Indices and Treatment Practice Patterns from the Multinational, Multicenter, Observational MERGE Registry. <i>Blood</i> , 2018, 132, 5461-5461.	1.4	1
183	Bone Marrow Transplantation for β^2 Thalassemia Major: Long Term Experience from a Single Centre in India.. <i>Blood</i> , 2007, 110, 1106-1106.	1.4	1
184	Fludarabine and Melphalan Conditioning Regimen in Young Patients with Acute Myeloid Leukemia in CR1 Undergoing a Matched Related Allogeneic Stem Cell Transplant: A Single Center Experience.. <i>Blood</i> , 2007, 110, 5049-5049.	1.4	1
185	Treatment of Relapsed and Refractory Acute Myeloid Leukemia with a Salvage FLAG-IDA Chemotherapy Regimen Followed by a HLA Matched Related Allogeneic PBSC Infusion without Additional Conditioning.. <i>Blood</i> , 2007, 110, 5050-5050.	1.4	1
186	A Fludarabine Based Conditioning Regimen Associated with A Good Survival Following HLA Identical Sibling/Family Donor Transplants in Patients with Aplastic Anemia.. <i>Blood</i> , 2009, 114, 1194-1194.	1.4	1
187	Trough Level of First Dose of Busulfan (Cmin1) Is a Stronger Predictor of Graft Rejection Than Steady State Concentration (Css1) In Patients with Beta Thalassemia Major Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2010, 116, 518-518.	1.4	1
188	Pharmacokinetics of Cyclophosphamide Metabolites Influence Outcome in Patients with β^2 -Thalassemia Major Undergoing Allogeneic HSCT. <i>Blood</i> , 2011, 118, 1941-1941.	1.4	1
189	Final Analysis of a Multi-Center Randomized Controlled Trial (IAPLSG04) to Study the Optimal Duration of Arsenic Trioxide Maintenance Therapy in the Treatment of Newly Diagnosed Acute Promyelocytic Leukemia. <i>Blood</i> , 2011, 118, 426-426.	1.4	1
190	NPM1 Mutated AML Is Associated With Lower Expression Of Poor Prognostic Markers BAALC, ERG and MN1 In Adult Patients With Acute Myeloid Leukaemia. <i>Blood</i> , 2013, 122, 4945-4945.	1.4	1
191	Prognostic Significance of Immunophenotypic Composition of B Cell Acute Lymphoblastic Leukemia at Diagnosis: A Novel Immunophenotype Based Risk Score. <i>Blood</i> , 2015, 126, 2620-2620.	1.4	1
192	Management of Relapsed Acute Promyelocytic Leukemia Post ATO Upfront Therapy: Open-Labeled Phase II Study Evaluating Role of Proteasome Inhibition. <i>Blood</i> , 2016, 128, 446-446.	1.4	1
193	Role of miRNA in Micro-Environment Mediated Drug Resistance in Acute Promyelocytic Leukemia to Arsenic Trioxide. <i>Blood</i> , 2016, 128, 5125-5125.	1.4	1
194	Revised myeloproliferative neoplasms working group consensus recommendations for diagnosis and management of primary myelofibrosis, polycythemia vera, and essential thrombocythemia. <i>Indian Journal of Medical and Paediatric Oncology</i> , 2018, 39, 503.	0.2	1
195	A Polymorphism In Interferon Gamma Gene Impacts the Extent of Joint Damage In Patients with Severe Hemophilia. <i>Blood</i> , 2010, 116, 546-546.	1.4	1
196	Expression Profiling Of Nuclear Hormone Receptors In Myeloid Leukemia Reveals Potential Novel Drug Targets For Combination Therapy. <i>Blood</i> , 2013, 122, 3855-3855.	1.4	1
197	V-raf murine sarcoma viral oncogene homolog B (BRAF) mutations in hairy cell leukaemia. <i>Indian Journal of Pathology and Microbiology</i> , 2015, 58, 62.	0.2	1
198	Donor Lymphocyte Infusion in Patients with Thalassemia Major Who Have Mixed Chimerism Following Allogeneic Stem Cell Transplant. <i>Blood</i> , 2015, 126, 1965-1965.	1.4	1

#	ARTICLE	IF	CITATIONS
199	Generic Intravenous Busulfan in Hematopoietic Stem Cell Transplantation: Relevance of Therapeutic Drug Monitoring. <i>Blood</i> , 2015, 126, 4322-4322.	1.4	1
200	Improved Outcomes with Allogeneic Stem Cell Transplantation for Aplastic Anaemia Using HLA Identical Sibling Donors: The Indian Stem Cell Transplant Registry (ISCTR) Experience. <i>Blood</i> , 2015, 126, 4386-4386.	1.4	1
201	Role of NF-E2 Related Factor 2 (NRF2) on Chemotherapy Resistance in Acute Myeloid Leukemia (AML) and the Effect of Pharmacological Inhibition of NRF2. <i>Blood</i> , 2015, 126, 1272-1272.	1.4	1
202	Efficacy of Second Line Agents Dapsone & Azathioprine in Children & Adults with Immune Thrombocytopenia: Single Centre Experience from India. <i>Blood</i> , 2015, 126, 1064-1064.	1.4	1
203	Fate of Ikaros in Multiple Myeloma Cells upon Treatment with Lenalidomide and Proteasome Inhibitor. <i>Blood</i> , 2016, 128, 3281-3281.	1.4	1
204	Hematology oncology practice in the Asia-Pacific APHCON survey results from the 6th international hematologic malignancies conference: bridging the gap 2015, Beijing, China. <i>Oncotarget</i> , 2017, 8, 41620-41630.	1.8	1
205	Fludarabine and Cyclophosphamide Based Conditioning Is Associated with Good Outcomes in Patients Undergoing Matched Sibling Donor Transplants for Aplastic Anaemia. <i>Blood</i> , 2019, 134, 3272-3272.	1.4	1
206	Targeting Extracellular Vesicle Secretion As a Strategy to Overcome Microenvironment Mediated Drug Resistance in Acute Myeloid Leukemia. <i>Blood</i> , 2019, 134, 3733-3733.	1.4	1
207	Real World Data of Concurrent Arsenic Trioxide and All-Trans Retinoic Acid with Minimal Use of Anthracycline in the Treatment of Acute Promyelocytic Leukemia. <i>Blood</i> , 2021, 138, 2338-2338.	1.4	1
208	Haploidentical Natural Killer Cell Therapy As an Adjunct to Stem Cell Transplantation for Refractory Acute Myeloid Leukemia. <i>Blood</i> , 2021, 138, 3827-3827.	1.4	1
209	Genetic Ablation of Nuclear Receptor Interacting Protein 1 (NRIP1) Sensitizes Acute Myeloid Leukemia Cells to Retinoic Acids. <i>Blood</i> , 2021, 138, 1146-1146.	1.4	1
210	Imatinib in India: Is the efficacy universal?. <i>Indian Journal of Medical and Paediatric Oncology</i> , 2005, 26, 3-4.	0.2	1
211	Cyclophosphamide induced haemorrhagic myocarditis-pericarditis: a rare but lethal complication in the setting of allogeneic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 0, , .	2.4	1
212	APL: Oh! What a tangled web we weave. <i>Blood</i> , 2017, 129, 1744-1745.	1.4	0
213	Establishing a comprehensive diagnosis of primary immunodeficiency diseases. <i>Blood Advances</i> , 2017, 1, 39-41.	5.2	0
214	APL in Developing Countries: ATO-Based Approach. , 2018, , 217-229.		0
215	NUDT15 c.415C>T Polymorphism Predicts 6-MP Induced Early Myelotoxicity in Patients with Acute Lymphoblastic Leukemia Undergoing Maintenance Therapy. <i>Pharmacogenomics and Personalized Medicine</i> , 2021, Volume 14, 1303-1313.	0.7	0
216	Pharmacogenetics of Cyclophosphamide in Patients with Beta Thalassemia Major Undergoing Bone Marrow Transplantation.. <i>Blood</i> , 2004, 104, 99-99.	1.4	0

#	ARTICLE	IF	CITATIONS
217	Molecular Genetics of Hereditary Prothrombin Deficiency in Indian Patients: Identification of a Novel Ala362→Thr (Prothrombin Vellore 1) Mutation by Conformation Sensitive Gel Electrophoresis.. Blood, 2004, 104, 1037-1037.	1.4	0
218	Cyclophosphamide Kinetics Influences Toxicity and Outcome of Bone Marrow Transplantation in Patients with β^2 -Thalassemia Major.. Blood, 2004, 104, 1820-1820.	1.4	0
219	Developing an Algorithm for Monitoring Chimerism after Allogeneic Bone Marrow Transplantation - A Single Centre Experience.. Blood, 2005, 106, 5301-5301.	1.4	0
220	Durable Remissions with Single Agent As2O3 in the Treatment of Newly Diagnosed Cases of Acute Promyelocytic Leukemia: Risk Stratification within This Group and Potential Impact on Future Algorithms.. Blood, 2005, 106, 892-892.	1.4	0
221	Surveyor α , β Nuclease: A New Rapid and Effective Strategy for Detection of Single Nucleotide Changes in Alpha Globin Genes.. Blood, 2005, 106, 3653-3653.	1.4	0
222	A Pilot Study of Rabbit Antithymocyte Globulin - TECELAC Combined with Cyclosporine and Prednisolone as Immunosuppressive Therapy for Severe Aplastic Anemia.. Blood, 2005, 106, 3749-3749.	1.4	0
223	Oral Prednisolone Produces a Durable Response in Pediatric Myelodysplastic Syndromes (MDS).. Blood, 2005, 106, 4906-4906.	1.4	0
224	The Role of Donor Lymphocyte Infusion (DLI) and Imatinib Mesylate in the Treatment of Relapse after Allogenic Stem Cell Transplant for Chronic Myeloid Leukemia.. Blood, 2005, 106, 5393-5393.	1.4	0
225	Fludarabine Based Conditioning for Allogeneic Transplantation in Severe Aplastic Anemia.. Blood, 2005, 106, 2029-2029.	1.4	0
226	A Low Intensity Protocol of Fludarabine, Busulfan and Cyclophosphamide Reduces Toxicity without Compromising Engraftment in Children Undergoing Allogeneic Bone Marrow Transplantation for Beta Thalassemia Major.. Blood, 2006, 108, 5366-5366.	1.4	0
227	Two Mutations (1717 T→C, GP IX;124del145, GPIb beta) Occur Frequently among Patients with Bernard Soulier Syndrome in India.. Blood, 2006, 108, 1096-1096.	1.4	0
228	IL-10 Polymorphism and TGF- β^2 Haplotypes Are Associated with Rejection of Graft in Children with Beta Thalassemia Major Undergoing Matched Related Bone Marrow Transplantation (BMT).. Blood, 2006, 108, 3011-3011.	1.4	0
229	Impact of Additional Cytogenetic Changes and FLT3 Mutations on the Outcome of Patients with Newly Diagnosed Acute Promyelocytic Leukaemia Treated with Single Agent Arsenic Trioxide.. Blood, 2006, 108, 2346-2346.	1.4	0
230	A New Stratification Strategy That Identifies a Subset of Class III Patients among Children with β^2 Thalassemia Major Undergoing a Matched Related Allogeneic Stem Cell Transplantation.. Blood, 2006, 108, 2996-2996.	1.4	0
231	Analysis of β^2 Globin Mutations in the Indian Population: Presence of Rare and Novel Mutations and Region Wise Heterogeneity.. Blood, 2007, 110, 3822-3822.	1.4	0
232	G-CSF Primed Bone Marrow Is Not Superior to Unprimed Bone Marrow as a Source of Stem Cells in HLA Matched Related Allogeneic SCT for β^2 Thalassemia Major.. Blood, 2007, 110, 5052-5052.	1.4	0
233	Molecular Analysis of WASP Gene - First Report from India.. Blood, 2007, 110, 3217-3217.	1.4	0
234	Kinetics of Molecular Response among Newly Diagnosed Patients with PML-RAR \pm Acute Promyelocytic Leukemia Treated with Arsenic Trioxide.. Blood, 2007, 110, 4366-4366.	1.4	0

#	ARTICLE	IF	CITATIONS
235	Minimal Residual Disease Monitoring in Patients with Newly Diagnosed Acute Promyelocytic Leukemia Treated with Arsenic Trioxide. Blood, 2008, 112, 2534-2534.	1.4	0
236	Population Pharmacokinetics of Busulfan in Patients with Beta Thalassaemia Major Undergoing HSCT Reveals Body Weight, GSTA1 and CYP3A4 Promoter Polymorphisms as Main Covariates Explaining the Inter-Individual Variation.. Blood, 2009, 114, 3349-3349.	1.4	0
237	Comparison of Differential Gene Expression Profiles of Relapsed Patients with Acute Promyelocytic Leukemia Treated with Arsenic Trioxide with the Profile of An Arsenic Trioxide Resistant NB4 Cell Line.. Blood, 2009, 114, 3460-3460.	1.4	0
238	Single Agent Arsenic Trioxide in the Treatment of Newly Diagnosed Acute Promyelocytic Leukemia: Long Term Follow-up Data.. Blood, 2009, 114, 846-846.	1.4	0
239	Fluorescent PCR Based Gene Dose Assessment for Detection of Deletion Mutations in the FIX Gene Among Carriers of Hemophilia B.. Blood, 2009, 114, 3486-3486.	1.4	0
240	Allogeneic Transplant In Children with Severe Aplastic Anemia â€œ Excellent Outcomes with the Use of a Fludarabine Based Conditioning Regimen. Blood, 2010, 116, 3519-3519.	1.4	0
241	Evaluation of Mechanisms of Resistance to Arsenic Trioxide In Patients with Acute Promyelocytic Leukemia. Blood, 2010, 116, 2746-2746.	1.4	0
242	Response to Immunosuppressive Therapy with Antithymocyte Globulin (ATG) In Older Patients with Aplastic Anemia. Blood, 2011, 118, 4374-4374.	1.4	0
243	Improved Clinical Outcomes of High Risk Î² Thalassaemia Major Patients Under Going a HLA Matched Related Allogeneic Stem Cell Transplant with the Use of a Treosulphan Based Conditioning Regimen and Peripheral Blood Stem Cell Grafts. Blood, 2011, 118, 1017-1017.	1.4	0
244	Expression of Ara-C Metabolizing Enzymes Mediates in Vitro Sensitivity to Ara-C in Primary AML Cells From Patients with Denovo AML,. Blood, 2011, 118, 3481-3481.	1.4	0
245	Carbonyl Reductase 1 Expression and Polymorphisms Influence Daunorubicin Metabolism in AML. Blood, 2011, 118, 2484-2484.	1.4	0
246	Rationale and Efficacy of Bortezomib in the Treatment of Acute Promyelocytic Leukemia in Combination with Arsenic Trioxide: In-Vitro and Phase I Data. Blood, 2011, 118, 947-947.	1.4	0
247	Role of Minimal Residual Disease Monitoring in Acute Promyelocytic Leukemia Treated with Arsenic Trioxide in Frontline Therapy. Blood, 2011, 118, 941-941.	1.4	0
248	RNA Expression and Polymorphisms in Imatinib Influx and Efflux Transporters Influence Molecular Response to Imatinib Therapy in Newly Diagnosed Patients with Chronic Myeloid Leukemia.. Blood, 2012, 120, 2785-2785.	1.4	0
249	A Phase II Study Using Post-Transplant Cyclophosphamide (PTC) As Graft Versus Host Disease (GVHD) Prophylaxis in Patients Undergoing HLA Matched Sibling Donor Stem Cell Transplant (SCT) for Severe Aplastic Anemia (SAA). Blood, 2012, 120, 4199-4199.	1.4	0
250	Community Based Evaluation of Prevalence of Inhibitors in Patients with Severe Hemophilia A in India and Their Correlation with Environmental and Genetic Factors. Blood, 2012, 120, 3380-3380.	1.4	0
251	Mechanism of Synergy Between Bortezomib and Arsenic Trioxide in Acute Promyelocytic Leukemia and Clinical Efficacy in Relapsed Patients. Blood, 2012, 120, 3607-3607.	1.4	0
252	ABC Transporter Expression in Acute Myeloid Leukemia: Association with in Vitro Cytotoxicity and Prognostic Markers. Blood, 2012, 120, 1438-1438.	1.4	0

#	ARTICLE	IF	CITATIONS
253	Genetic Diagnosis of Inherited Bleeding Disorders in 1250 Proband From India: A Single Centre Experience. <i>Blood</i> , 2012, 120, 1127-1127.	1.4	0
254	High Expression of p53 and Growth Differentiation Factor-15 in Beta-Thalassemia.. <i>Blood</i> , 2012, 120, 2130-2130.	1.4	0
255	Patterns of Immune Reconstitution in Patients with Acute Promyelocytic Leukemia Treated with Single Agent Arsenic Trioxide and Its Impact On Time to Molecular Remission. <i>Blood</i> , 2012, 120, 3552-3552.	1.4	0
256	Delay In Onset Of First Transfusion and Increased Risk Of Graft Rejection In β^2 Thalassemia Patients Undergoing a HLA Matched Related Allogeneic Stem Cell Transplant. <i>Blood</i> , 2013, 122, 701-701.	1.4	0
257	Clinical Profile and Outcome Of Patients With Graft Rejection Following Related HLA Matched Allogeneic Stem Cell Transplant For β^2 Thalassemia Major. <i>Blood</i> , 2013, 122, 4546-4546.	1.4	0
258	pVAX14 DNA, a Non-Specific DNA Vaccine, Improves Survival In An Acute Promyelocytic Leukemia (APL) Mouse Model Treated With All-Trans Retinoic Acid (ATRA) and Arsenic Trioxide (ATO) and Targets Leukemia Initiating Cells (LICs). <i>Blood</i> , 2013, 122, 235-235.	1.4	0
259	Pharmacokinetics Of a Generic Formulation Of Intravenous Busulfan (BUCELON 60 μ g) In Patients Undergoing Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2013, 122, 3280-3280.	1.4	0
260	Population Pharmacokinetics of Daunorubicin in AML: Influence on Clinical Outcome. <i>Blood</i> , 2014, 124, 902-902.	1.4	0
261	Proteasome Activity Is Dispensable for the Degradation of PML-RAR α : Efficacy of Bortezomib Along with Arsenic Trioxide in the Treatment of Arsenic Sensitive and Resistant Acute Promyelocytic Leukemia. <i>Blood</i> , 2014, 124, 3741-3741.	1.4	0
262	The Addition of Meloxicam to G-CSF Is Associated with Good Mobilization Rates, Faster Engraftment and Reduced Toxicity and Hospital Stay after Autologous Stem Cell Transplantation – a Phase II Study. <i>Blood</i> , 2014, 124, 2455-2455.	1.4	0
263	Pre-Transplant Consolidation and Cost Effectiveness of RIC Allogeneic SCT in Patients of AML-CR1 in India. <i>Blood</i> , 2014, 124, 2462-2462.	1.4	0
264	Pharmacokinetics of Fludarabine in Patients with Aplastic Anemia Undergoing Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2014, 124, 3884-3884.	1.4	0
265	Coagulopathy in Acute Promyelocytic Leukemia: Strategies to Improve Assessment of Hemostatic Risk. <i>Blood</i> , 2015, 126, 3758-3758.	1.4	0
266	Autologous Transplant, and Not ATO Alone, Remains the Preferred Therapy for Relapsed APL: A Report from the CIBMTR, EBMT and Two Specialized Centers. <i>Blood</i> , 2015, 126, 928-928.	1.4	0
267	Adult Acute Lymphoblastic Leukemia: A Cost Effective Strategy and Limitations of Intensification of Therapy in India. <i>Blood</i> , 2015, 126, 3732-3732.	1.4	0
268	Osteoblast Differentiation of Stromal Cells Induced By Leukemic Cells. <i>Blood</i> , 2016, 128, 5062-5062.	1.4	0
269	Alteration of the Hematopoietic Components, Mesenchymal Stromal Cells and Vascular Elements in the Bone Marrow Niche in Myelodysplastic Syndrome: Refractory Cytopenia with Multilineage Dysplasia. <i>Blood</i> , 2016, 128, 5516-5516.	1.4	0
270	Multi-Drug Resistant Organisms Are Common in Fecal Surveillance Cultures and Do Not Predict Bacteremia but Correlate with Poorer Outcomes in Patients Undergoing Allogeneic Stem Cell Transplants. <i>Blood</i> , 2016, 128, 3406-3406.	1.4	0

#	ARTICLE	IF	CITATIONS
271	Second Hematopoietic SCT for Thalassemia Major: Improved Clinical Outcomes with a Treosulfan Based Conditioning Regimen. Blood, 2016, 128, 2201-2201.	1.4	0
272	Role of Pre-Transplant Cardiac and Hepatic T2* Magnetic Resonance for Risk Assessment in Patients with Thalassemia Major Undergoing an Allogeneic Stem Cell Transplantation. Blood, 2016, 128, 2200-2200.	1.4	0
273	Iron Reduction Therapy in Ex-Thalasseemics - Long Term Outcome. Blood, 2018, 132, 4591-4591.	1.4	0
274	Targeted IV Vs Oral Busulfan in Very Young Children with Thalassemia Major Undergoing Matched Allogeneic Haematopoietic Stem Cell Transplantation. Blood, 2018, 132, 5707-5707.	1.4	0
275	Hematological Cancer Consortium: Multi-Center Acute Lymphoblastic Leukemia Registry Data from India. Blood, 2018, 132, 1374-1374.	1.4	0
276	Impact of Graft Versus Host Disease on Outcome of Allogeneic Haematopoietic Stem Cell Transplantation for Thalassemia Major - Comparison of Bone Marrow Vs Peripheral Blood Stem Cell Grafts. Blood, 2019, 134, 4537-4537.	1.4	0
277	Treosulfan Metabolite (S, S-EBDM) Pharmacokinetics Influences Regimen Related Toxicity in Patients with Beta Thalassemia Major Undergoing HSCT. Blood, 2019, 134, 1977-1977.	1.4	0
278	Germline Variants Contribute Significantly to the Pathogenesis of Aplastic Anemia in India. Blood, 2021, 138, 1105-1105.	1.4	0
279	Endothelial Activation and Stress Index (EASIX) Measured Pre-Transplant Identifies a Subgroup with High Transplant Related Mortality in Patients with Thalassemia Undergoing Stem Cell Transplantation Using Thiotepa-Treosulfan-Fludarabine Conditioning. Blood, 2021, 138, 1781-1781.	1.4	0
280	Arsenic Trioxide Reprograms the Bone-Marrow Microenvironment to Sensitize Minimal Residual Disease in Acute Myeloid Leukemia. Blood, 2021, 138, 1166-1166.	1.4	0
281	Combining Arsenic Trioxide and Mitocans Selectively Disrupts Cellular Energetics in Acute Myeloid Leukemia. Blood, 2021, 138, 2245-2245.	1.4	0
282	Ehl Factors at Lower Than Standard Dose Achieve Satisfactory Surgical Haemostasis in Haemophilia. Blood, 2020, 136, 25-26.	1.4	0